Cytiva, a Danaher company in the life sciences industry and WhiteLab Genomics, a biotech company specialising in genomic artificial intelligence, have announced a collaboration to accelerate the development of next-generation genomic medicines.
As part of this partnership, WhiteLab Genomics will use its proprietary AI-powered technology to optimise and reduce stable cell line development timelines.
Through analysing complex biological data with advanced data analysis, WhiteLab’s platform will help improve the stable cell line clone selection process, all through computer simulations.
“Through the integration of AI-driven predictive modelling into adeno-associated virus (AAV) development workflows, we aim to reduce development timelines and associated costs by up to 70%,” said David Del Bourgo, CEO and co-founder of WhiteLab Genomics.
“This is a significant impact when the total cost of bringing a genomic medicine to market can approach nearly $2 billion, enabling a more efficient, scalable path to clinical and commercial readiness in genomic medicine.”
Combined with Cytiva’s expertise in stable cell lines for AAV production, the collaboration aims to benefit researchers in advanced therapies and their patients.
Emmanuel Abate, President of Genomic Medicine, Cytiva, said: “Genomic medicines will be critical to address some of the world’s greatest health challenges."
"By combining Cytiva’s experience with WhiteLab’s technology, we intend to help manufacturers reach clinical and regulatory milestones faster, benefiting patients around the world."